The FDA rejected Lykos Therapeutics’ application for MDMA-assisted therapy for PTSD in August 2024, and as of mid-2026 that decision stands. MDMA remains a Schedule I substance in the United States, meaning the only legal access pathways are through active...
Ketamine vs. esketamine (Spravato) is one of the most common points of confusion for people exploring treatment-resistant depression options. Both work through a similar mechanism in the brain, but they differ in molecular composition, route of administration, FDA...
Research into psilocybin aging effects is accelerating, with preclinical studies pointing to neuroplasticity promotion, reduced neuroinflammation, and improvements in longevity biomarkers. The findings are genuinely interesting, but human data remains limited, and...
Talking to your doctor about psychedelic therapy is one of the most common points where people get stuck. This guide walks you through how to frame the conversation, what questions to bring, and what to understand about medications like SSRIs before you book that...
5-MeO-DMT therapy is attracting serious interest from researchers, executives, and people seeking relief from depression, anxiety, and trauma. The compound is potent, fast-acting, and increasingly the subject of clinical investigation. It also carries real risks that...
Psilocybin OCD treatment is a small but growing area of clinical research, with early data suggesting meaningful symptom reductions for people who have not responded to standard medications or therapy. The evidence is still in early phases, but the signals are...
